On November 3, 2026, JPMorgan Chase & Co. acquired 477,103 shares of SINOPHARM (01099) (H shares) by taking a security interest in shares via an off-exchange transaction at an average of HKD 16.6783 per share, involving about HKD 7.96 million, which was not matched on the SEHK open market (nature of consideration: cash).
Prior to the acquisition, JPMorgan Chase & Co.’s long position in SINOPHARM was 67.00 million shares, representing 4.99%; following the acquisition, the holding changed to 67.47 million shares, with the long position ratio rising to 5.02%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments